EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure

Michael Ip, Varun Chaudhary, Fanyin He, Emmanuel Bouillaud, Yongsoo Kim, Franklin Igwe, Michael Singer

Ophthalmology Retina · 2026

DOI: 10.1016/j.oret.2025.10.013 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmology Retina, 2026. Verfasst von Michael Ip und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California; Doheny Eye Institute, Los Angeles, C…. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Macular Edema, Recombinant Fusion Proteins, Visual Acuity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyMacular EdemaRecombinant Fusion ProteinsVisual AcuityReceptors, Vascular Endothelial Growth FactorAntibodies, Monoclonal, HumanizedMacula LuteaHumansIntravitreal InjectionsMaleFemaleMiddle AgedTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsTreatment OutcomeFollow-Up StudiesAgedDouble-Blind MethodDose-Response Relationship, DrugFluorescein AngiographyFundus Oculi

Stichwörter der Autor:innen

Anti-VEGFBest-corrected visual acuityBrolucizumabDiabetic macular edemaPost hoc

Substanzen

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorafliberceptbrolucizumabVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, California; Doheny Eye Institute, Los Angeles, California. Electronic address: MIp@doheny.org.
  • Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
  • Beijing Novartis Pharma Co., Ltd., Beijing, China.
  • Novartis Pharma AG, Basel, Switzerland.
  • Medical Center Ophthalmology Associates, San Antonio, Texas.

Förderung

  • Novartis

Zitieren

APA

Ip, M., Chaudhary, V., He, F., Bouillaud, E., Kim, Y., Igwe, F., & Singer, M. (2026). Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2025.10.013

Vancouver

Ip M, Chaudhary V, He F, Bouillaud E, Kim Y, Igwe F, et al. Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure. Ophthalmology Retina. 2026. doi:10.1016/j.oret.2025.10.013

BibTeX
@article{Ip2026,
  author = {Ip, Michael and Chaudhary, Varun and He, Fanyin and Bouillaud, Emmanuel and Kim, Yongsoo and Igwe, Franklin and Singer, Michael},
  title = {Brolucizumab for Diabetic Macular Edema in Participants with/without prior Anti-VEGF Exposure},
  journal = {Ophthalmology Retina},
  year = {2026},
  doi = {10.1016/j.oret.2025.10.013}
}
Kostenlos starten →